Tongyu Lin

Dr. Tongyu Lin


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2010 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
XPXing‐Xiang Pu
Xing‐Xiang Pu
GHGuo‐Liang Huang
Guo‐Liang Huang
HGHong‐Qiang Guo
Hong‐Qiang Guo
CGCheng‐Cheng Guo
Cheng‐Cheng Guo
HLHaoran Li
Haoran Li
Tongyu LinTongyu Lin
Tongyu Lin

5 July 2023 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
HHHuageng Huang
Huageng Huang
YYYuyi Yao
Yuyi Yao
XDXinyi Deng
Xinyi Deng
ZHZongyao Huang
Zongyao Huang
YCYungchang Chen
Yungchang Chen
Tongyu LinTongyu Lin
Tongyu Lin
Nasopharyngeal carcinoma (NPC) is an epithelial tumor located in the nasopharynx and is highly associated with Epstein‑Barr virus (EBV) infection. Although radiotherapy alone can cure ~90% of patients with early‑stage disease, >70% of patients with NPC have locoregionally advanced or metastatic disease at the first diagnosis due to the insidious and aggressive nature of NPC. After comprehensive radiochemotherapy, 20‑30% of patients with advanced NPC still fail treatment, mainly due to recurrence and/or metastasis (R/M). Conventional salvage treatments, such as radiotherapy, chemotherapy and surgery, are suboptimal and frequently accompanied by severe adverse effects and limited efficacy. In recent years, immunotherapy has emerged as a promising treatment modality for R/M NPC. An increasing number of clinical studies have investigated the safety and efficacy of immunotherapy for advanced NPC and have shown considerable progress. In the present review, the rationale for the use of immunotherapy to treat NPC was summarized and the current status, progress and challenges of NPC clinical research on different immunotherapeutic approaches were highlighted, including immune checkpoint inhibitors, vaccines, immunomodulators, adoptive cell transfer and EBV‑specific monoclonal antibodies. The comprehensive overview of immunotherapy in NPC may provide insight for clinical practice and future investigation.

5 August 2020 in Leukemia
Verified
Journal Article
Open access
PDF file
JLJing Quan Lim
Jing Quan Lim
DHDachuan Huang
Dachuan Huang
TTTiffany Tang
Tiffany Tang
DTDaryl Tan
Daryl Tan
YLYurike Laurensia
Yurike Laurensia
SLSoon Thye Lim
Soon Thye Lim

17 February 2020 in Leukemia
Verified
Journal Article
Open access
PDF file
HHHuangming Hong
Huangming Hong
YLYexiong Li
Yexiong Li
SLSoon Thye Lim
Soon Thye Lim
CLChaoyong Liang
Chaoyong Liang
HHHe Huang
He Huang
Tongyu LinTongyu Lin
Tongyu Lin

16 December 2017 in Chinese Journal of Cancer
Verified
Journal Article
Open access
PDF file
LHLi-Yang Hu
Li-Yang Hu
XXXiao-Lu Xu
Xiao-Lu Xu
HRHuilan Rao
Huilan Rao
JCJie Chen
Jie Chen
PWPeng Wangqing
Peng Wangqing
QCQing-Qing Cai
Qing-Qing Cai
The programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway inhibits the activation of T cells and plays a crucial role in the negative regulation of cellular and humoral immune responses. Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults. In the present study, we aimed to detect the expression of PD-L1 in DLBCL and to analyze its relationship with prognosis. We reviewed medical records of 204 newly diagnosed DLBCL patients in Sun Yat-sen University Cancer Center between October 2005 and August 2012. The expression of PD-L1 in tumor tissues from these 204 patients was detected using immunohistochemical (IHC) assay. The expression of anaplastic lymphoma kinase (ALK), CD5, CD30, and C-Myc in tumor specimens from 109 patients was detected using IHC, and Epstein–Barr virus (EBV)-encoded RNAs (EBERs) were detected using fluorescence in situ hybridization. The Spearman method was used for correlation analysis. The Kaplan–Meier method with log-rank test was used for univariate analysis. Cox proportional hazards model was used for multivariate analysis. Of the 204 patients, 100 (49.0%) were PD-L1-positive in tumor cells and 44 (21.6%) were PD-L1-positive in tumor microenvironment. PD-L1 expression in tumor cells and tumor microenvironment were more common in the non-germinal center B-cell-like (GCB) subtype than in the GCB subtype (P = 0.02 and P = 0.04). Patients with PD-L1 expression in tumor microenvironment were more likely to be resistant to first-line chemotherapy when compared with the patients without PD-L1 expression in tumor microenvironment (P = 0.03). PD-L1 expression in tumor microenvironment was negatively correlated with C-Myc expression (r = − 0.20, P = 0.04). No correlations were detected between PD-L1 expression and the expression of ALK, CD5, and CD30 as well as EBERs. The 5-year overall survival (OS) rates were 50.0% and 67.3% in patients with and without PD-L1 expression in tumor cells (P = 0.02). PD-L1 expression in tumor cells was an independent risk predictor for OS (P < 0.01). PD-L1 expression is more common in the non-GCB subtype than in the GCB subtype. PD-L1 expression in tumor microenvironment has a negative correlation with C-Myc. PD-L1 positivity predicts short survival in DLBCL patients. For patients with PD-L1 expression, more strategy such as anti-PD-L1 antibody treatment should be recommended.

1 October 2021 in European Journal of Cancer
Verified
Journal Article
Open access
YGYe Guo
Ye Guo
YLYi Luo
Yi Luo
QZQingyuan Zhang
Qingyuan Zhang
XHXiaoming Huang
Xiaoming Huang
ZLZhengdong Li
Zhengdong Li
Tongyu LinTongyu Lin
Tongyu Lin
The EXTREME regimen (chemotherapy [CT; cisplatin/carboplatin and 5-fluorouracil]) plus cetuximab is a standard-of-care first-line (1L) treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), as supported by international guidelines. The phase III CHANGE-2 trial assessed the efficacy and safety of a modified CT regimen (with a reduced dose of both components) and cetuximab versus CT for the 1L treatment of Chinese patients with R/M SCCHN. Patients were randomised to receive up to six cycles of CT plus cetuximab followed by cetuximab maintenance until progressive disease or CT alone. The primary end-point was the progression-free survival (PFS) time assessed by the independent review committee (IRC). Overall, 243 patients were randomised (164 to CT plus cetuximab; 79 to CT). The hazard ratios for PFS by IRC and overall survival (OS) were 0.57 (95% CI: 0.40-0.80; median: 5.5 versus 4.2 months) and 0.69 (95% CI: 0.50-0.93; median: 11.1 versus 8.9 months), respectively, in favour of CT plus cetuximab. The objective response rates (ORR) by IRC were 50.0% and 26.6% with CT plus cetuximab and CT treatment, respectively. Treatment-emergent adverse events of maximum grade 3 or 4 occurred in 61.3% (CT plus cetuximab) and 48.7% (CT) of patients. CHANGE-2 showed an improved median PFS, median OS and ORR with the addition of cetuximab to a modified platinum/5-fluorouracil regimen, with no new or unexpected safety findings, thereby confirming CT plus cetuximab as an effective and safe 1L treatment for Chinese patients with R/M SCCHN. NCT02383966.